Deanna G. Brockman

Deanna G. Brockman

Auto-generated profile, based on publicly available information

Deanna G. Brockman

Color Genetics, Burlingame, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
DBDeanna G. Brockman
Deanna G. Brockman
LPLia Petronio
Lia Petronio
JDJacqueline S. Dron
Jacqueline S. Dron
BKBum Chul Kwon
Bum Chul Kwon
TVTrish Vosburg
Trish Vosburg
AKAmit V. Khera
Amit V. Khera
Background: Polygenic scores—which quantify inherited risk by integrating information from many common sites of DNA variation—may enable a tailored approach to clinical medicine. However, alongside considerable enthusiasm, we and others have highlighted a lack of standardized approaches for score disclosure. Here, we review the landscape of polygenic score reporting and describe a generalizable approach for development of a polygenic score disclosure tool for coronary artery disease.Methods: We assembled a working group of clinicians, geneticists, data visualization specialists, and software developers. The group reviewed existing polygenic score reports and then designed a two-page mock report for coronary artery disease. We then conducted a qualitative user-experience study with this report using an interview guide focused on comprehension, experience, and attitudes. Interviews were transcribed and analyzed for themes identification to inform report revision.Results: Review of nine existing polygenic score reports from commercial and academic groups demonstrated significant heterogeneity, reinforcing the need for additional efforts to study and standardize score disclosure. Using a newly developed mock score report, we conducted interviews with ten adult individuals (50% females, 70% without prior genetic testing experience, age range 20–70 years) recruited via an online platform. We identified three themes from interviews: (1) visual elements, such as color and simple graphics, enable participants to interpret, relate to, and contextualize their polygenic score, (2) word-based descriptions of risk and polygenic scores presented as percentiles were the best recognized and understood, (3) participants had varying levels of interest in understanding complex genomic information and therefore would benefit from additional resources that can adapt to their individual needs in real time. In response to user feedback, colors used for communicating risk were modified to minimize unintended color associations and odds ratios were removed. All 10 participants expressed interest in receiving a polygenic score report based on their personal genomic information.Conclusions: Our findings describe a generalizable approach to develop a polygenic score report understandable by potential patients. Although additional studies are needed across a wider spectrum of patient populations, these results are likely to inform ongoing efforts related to polygenic score disclosure within clinical practice.

11 May 2021 in Genetics in Medicine
Verified
Journal Article
Closed access
DBDeanna G. Brockman
Deanna G. Brockman
CAChristina A. Austin-Tse
Christina A. Austin-Tse
RPRenée C. Pelletier
Renée C. Pelletier
CHCaroline Harley
Caroline Harley
CPCandace Patterson
Candace Patterson
MUMiriam S. Udler
Miriam S. Udler

1 April 2021 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
NRNicholas J. Reid
Nicholas J. Reid
DBDeanna G. Brockman
Deanna G. Brockman
CLCourtney Elisabeth Leonard
Courtney Elisabeth Leonard
RPRenee Pelletier
Renee Pelletier
AKAmit V. Khera
Amit V. Khera

29 November 2019 in medRxiv
Verified
Preprint
Open access
PDF file
AFAkl C. Fahed
Akl C. Fahed
MWMinxian Wang
Minxian Wang
JHJulian R. Homburger
Julian R. Homburger
APAniruddh P. Patel
Aniruddh P. Patel
ABAlexander G. Bick
Alexander G. Bick
AKAmit V. Khera
Amit V. Khera
Background: Genetic variation can predispose to disease both through (i) monogenic risk variants in specific genes that disrupt a specific physiologic pathway and have a large effect on disease risk and (ii) polygenic risk that involves large numbers of variants of small effect that affect many different pathways. Few studies have explored the interaction between monogenic risk variants and polygenic risk. Methods: We identified monogenic risk variants and calculated polygenic scores for three diseases, coronary artery disease, breast cancer, and colorectal cancer, in three study populations — case-control cohorts for coronary artery disease (UK Biobank; N=12,879) and breast cancer (Color Genomics; N=19,264), and an independent cohort of 49,738 additional UK Biobank participants. Results: In the coronary artery disease case-control cohort, increased risk for carriers of a monogenic variant ranged from 1.3-fold for those in the lowest polygenic score quintile to 12.6-fold for those in the highest. For breast cancer, increased risk ranged from 2.4 to 6.9-fold across polygenic score quintiles. Among the 49,738 UK Biobank participants who carried a monogenic risk variant, the probability of disease at age 75 years was strongly modified by polygenic risk. Across individuals in the lowest to highest percentiles of polygenic risk, the probability of disease ranged from 17% to 78% for coronary artery disease; 13% to 76% for breast cancer; and 11% to 80% for colon cancer. Conclusions: For three important genomic conditions, polygenic risk powerfully modifies the risk conferred by monogenic risk variants.

8 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
HWHannah Wand
Hannah Wand
SLSamuel A. Lambert
Samuel A. Lambert
CTCecelia Tamburro
Cecelia Tamburro
MIMichael A. Iacocca
Michael A. Iacocca
JOJack W. O’sullivan
Jack W. O’sullivan
GWGenevieve L Wojcik
Genevieve L Wojcik
Polygenic risk scores (PRS), often aggregating the results from genome-wide association studies, can bridge the gap between the initial variant discovery efforts and disease risk estimation for clinical applications. However, there is remarkable heterogeneity in the reporting of these risk scores due to a lack of adherence to reporting standards and no accepted standards suited for the current state of PRS development and application. This lack of adherence and best practices hinders the translation of PRS into clinical care. The ClinGen Complex Disease Working Group, in a collaboration with the Polygenic Score (PGS) Catalog, have developed a novel PRS Reporting Statement (PRS-RS), updating previous standards to the current state of the field and to enable downstream utility. Drawing upon experts in epidemiology, statistics, disease-specific applications, implementation, and policy, this 23-item reporting framework defines the minimal information needed to interpret and evaluate a PRS, especially with respect to any downstream clinical applications. Items span detailed descriptions of the study population (recruitment method, key demographics, inclusion/exclusion criteria, and phenotype definition), statistical methods for both PRS development and validation, and considerations for potential limitations of the published risk score and downstream clinical utility. Additionally, emphasis has been placed on data availability and transparency to facilitate reproducibility and benchmarking against other PRS, such as deposition in the publicly available PGS Catalog ( www.PGScatalog.org ). By providing these criteria in a structured format that builds upon existing standards and ontologies, the use of this framework in publishing PRS will facilitate translation of PRS into clinical care and progress towards defining best practices. Summary: In recent years, polygenic risk scores (PRS) have become an increasingly studied tool to capture the genome-wide liability underlying many human traits and diseases, hoping to better inform an individual’s genetic risk. However, a lack of tailored reporting standards has hindered the translation of this important tool into clinical and public health practice with the heterogeneous underreporting of details necessary for benchmarking and reproducibility. To address this gap, the ClinGen Complex Disease Working Group and Polygenic Score (PGS) Catalog have collaborated to develop the 23-item Polygenic Risk Score Reporting Statement (PRS-RS). This framework provides the minimal information expected of authors to promote the validity, transparency, and reproducibility of PRS by requiring authors to detail the study population, statistical methods, and potential clinical utility of a published score. The widespread adoption of this framework will encourage rigorous methodological consideration and facilitate benchmarking to ensure high quality scores are translated into the clinic.

14 September 2022 in arXiv
Verified
Preprint
Open access
PDF file
BKBum Chul Kwon
Bum Chul Kwon
UKUri Kartoun
Uri Kartoun
SKShaan Khurshid
Shaan Khurshid
MYMikhail Yurochkin
Mikhail Yurochkin
SMSubha Maity
Subha Maity
KNKenney Ng
Kenney Ng
Disease risk models can identify high-risk patients and help clinicians provide more personalized care. However, risk models developed on one dataset may not generalize across diverse subpopulations of patients in different datasets and may have unexpected performance. It is challenging for clinical researchers to inspect risk models across different subgroups without any tools. Therefore, we developed an interactive visualization system called RMExplorer (Risk Model Explorer) to enable interactive risk model assessment. Specifically, the system allows users to define subgroups of patients by selecting clinical, demographic, or other characteristics, to explore the performance and fairness of risk models on the subgroups, and to understand the feature contributions to risk scores. To demonstrate the usefulness of the tool, we conduct a case study, where we use RMExplorer to explore three atrial fibrillation risk models by applying them to the UK Biobank dataset of 445,329 individuals. RMExplorer can help researchers to evaluate the performance and biases of risk models on subpopulations of interest in their data.